31 completed, 14 terminated, 1 active not recruiting, 1 withdrawn. 47 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 47 | Completed 31, Terminated 14, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 8 | Completed 4, Terminated 3, Withdrawn 1 |
Follow Recurrent Adult Diffuse Small Cleaved Cell Lymphoma: new trials by email Literature Review of Recurrent Adult Diffuse Small Cleaved Cell Lymphoma trials Research Report on Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma rituximab, lenalidomide, romidepsin - B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 1 / Phase 2 | Withdrawn | Mayo Clinic | 2016-10-01 | 2016-08-11 | |
| CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride, rituximab - B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Wake Forest University Health Sciences | 1 | 2014-12-01 | 2018-07-02 |
| Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study - Adult B Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 72 | 2014-09-01 | 2015-08-20 |
| MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Morphotek | 27 | 2013-11-01 | 2016-01-08 |
| Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells, autologous hematopoietic stem cell transplantation, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 30 | 2013-10-08 | 2026-06-25 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Northwestern University | 20 | 2013-03-05 | 2021-09-01 |
| Ipilimumab and Local Radiation for Selected Solid Tumors Ipilimumab, Radiation therapy - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Terminated | Stanford University | 3 | 2013-02-01 | 2024-01-24 |
| Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies therapeutic allogeneic lymphocytes - Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) | Phase 1 | Completed | Robert Lowsky | 16 | 2012-01-01 | 2023-11-22 |
| Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Bendamustine Hydrochloride, Pharmacological Study, Rituximab - Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 43 | 2011-07-01 | 2019-12-16 |
| Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies fludarabine phosphate, methoxyamine, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Case Comprehensive Cancer Center | 20 | 2011-05-01 | 2015-08-13 |
| RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors gamma-secretase/Notch signalling pathway inhibitor RO4929097, capecitabine, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2010-06-01 | 2014-11-07 |
| AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma Pharmacodynamic Studies, Fatigue Inventory, Pharmacogenomic studies - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Amir Mortazavi | 44 | 2010-05-04 | 2018-06-04 |
| Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma lenalidomide, vorinostat, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Terminated | City of Hope Medical Center | 30 | 2010-05-01 | 2010-12-09 |
| Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma lenalidomide, rituximab, polymerase chain reaction - Adult Non-Hodgkin Lymphoma, Adult Grade III Lymphomatoid Granulomatosis | Phase 1 | Terminated | Case Comprehensive Cancer Center | 5 | 2010-01-01 | 2015-11-26 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy sunitinib malate, pharmacological study, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2009-08-01 | 2014-03-17 |
| Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery R-(-)-gossypol acetic acid, paclitaxel, carboplatin - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 36 | 2009-07-01 | 2013-01-10 |
| FAU in Treating Patients With Advanced Solid Tumors or Lymphoma 2'-F-ara-deoxyuridine, positron emission tomography, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 12 | 2009-07-01 | 2014-01-07 |
| Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery Dasatinib, Pharmacological Study - Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 80 | 2008-10-01 | 2015-07-02 |
| Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma DI-Leu16-IL2 immunocytokine, rituximab, flow cytometry - Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma | Phase 1 | Completed | City of Hope Medical Center | 9 | 2008-03-17 | 2026-10-23 |
| Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma vorinostat, rituximab, ifosfamide - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 / Phase 2 | Completed | University of Washington | 29 | 2007-12-01 | 2017-05-25 |
Showing 20 of 47. Sign in to see all of them.
Lymphoma, B-Cell, Marginal Zone (47) · Lymphoma, Follicular (47) · Lymphoma, Non-Hodgkin (47) · Lymphoma, Mantle-Cell (46) · Lymphoma, Large B-Cell, Diffuse (45) · Burkitt Lymphoma (43) · Leukemia, Lymphocytic, Chronic, B-Cell (43) · Lymphoma, Large-Cell, Immunoblastic (42) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (42) · Waldenstrom Macroglobulinemia (40) · Hodgkin Disease (31) · Intraocular Lymphoma (30) · Mycosis Fungoides (30) · Sezary Syndrome (30) · Lymphoma, Large-Cell, Anaplastic (29)
Hematologic Diseases (47) · Hemic and Lymphatic Diseases (47) · Immune System Diseases (47) · Immunoproliferative Disorders (47) · Lymphatic Diseases (47) · Lymphoma (47) · Lymphoma, B-Cell (47) · Lymphoproliferative Disorders (47) · Neoplasms (47) · Neoplasms by Histologic Type (47) · Leukemia (45) · Leukemia, Lymphoid (45) · Disease Attributes (44) · Pathologic Processes (44) · Pathological Conditions, Signs and Symptoms (44)
Rituximab (9) · Bortezomib (5) · fludarabine phosphate (5) · Peripheral Blood Stem Cell Transplantation (4) · Vorinostat (4) · tanespimycin (4) · Flow Cytometry (3) · Lenalidomide (3) · Bendamustine Hydrochloride (2) · CTLA-4 Antigen (2) · Carboplatin (2) · Cyclosporine (2) · Gemcitabine (2) · Ipilimumab (2) · Mycophenolic Acid (2)
National Cancer Institute (NCI) (30) · Fred Hutchinson Cancer Center (4) · City of Hope Medical Center (3) · Case Comprehensive Cancer Center (2) · Amir Mortazavi (1) · Mayo Clinic (1) · Morphotek (1) · Northwestern University (1) · Robert Lowsky (1) · Stanford University (1) · University of Washington (1) · Wake Forest University Health Sciences (1)
United States (45) · Canada (2) · Italy (2) · Germany (1)
Ajay Gopal (2) · Patricia LoRusso (2) · Ramesh Ramanathan (2) · Adam Petrich, MD (1) · Amir Mortazavi, MD (1) · Antonius Miller (1) · Brenda Cooper (1) · Brenda Sandmaier (1) · Chandra Belani (1) · Charles Erlichman (1) · Daniel Mulkerin (1) · David Hong (1) · David Maloney (1) · Elizabeth Budde (1)
PMID 32499241, PMID 22259028, PMID 24241210, PMID 24474568, PMID 24530971, PMID 26943915, PMID 27118452, PMID 28270022, PMID 28314788, PMID 29292843, PMID 29572391, PMID 31388792, PMID 33492438, PMID 34515338
U01CA062487 (5), U01CA062491 (5), U01CA099168 (5), U01CA062502 (4), P30CA015083 (3), P30CA015704 (3), U01CA062505 (3), U01CA069912 (3), U01CA076576 (3), P01CA044991 (2), P30CA016058 (2), P50CA107399 (2), U01CA069852 (2), U01CA121947 (2), U01CA132123 (2)